Arthritis Research & Therapy (Feb 2021)

Advanced machine learning for predicting individual risk of flares in rheumatoid arthritis patients tapering biologic drugs

  • Asmir Vodencarevic,
  • Koray Tascilar,
  • Fabian Hartmann,
  • Michaela Reiser,
  • Axel J. Hueber,
  • Judith Haschka,
  • Sara Bayat,
  • Timo Meinderink,
  • Johannes Knitza,
  • Larissa Mendez,
  • Melanie Hagen,
  • Gerhard Krönke,
  • Jürgen Rech,
  • Bernhard Manger,
  • Arnd Kleyer,
  • Marcus Zimmermann-Rittereiser,
  • Georg Schett,
  • David Simon,
  • on behalf of the RETRO study group

DOI
https://doi.org/10.1186/s13075-021-02439-5
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Background Biological disease-modifying anti-rheumatic drugs (bDMARDs) can be tapered in some rheumatoid arthritis (RA) patients in sustained remission. The purpose of this study was to assess the feasibility of building a model to estimate the individual flare probability in RA patients tapering bDMARDs using machine learning methods. Methods Longitudinal clinical data of RA patients on bDMARDs from a randomized controlled trial of treatment withdrawal (RETRO) were used to build a predictive model to estimate the probability of a flare. Four basic machine learning models were trained, and their predictions were additionally combined to train an ensemble learning method, a stacking meta-classifier model to predict the individual flare probability within 14 weeks after each visit. Prediction performance was estimated using nested cross-validation as the area under the receiver operating curve (AUROC). Predictor importance was estimated using the permutation importance approach. Results Data of 135 visits from 41 patients were included. A model selection approach based on nested cross-validation was implemented to find the most suitable modeling formalism for the flare prediction task as well as the optimal model hyper-parameters. Moreover, an approach based on stacking different classifiers was successfully applied to create a powerful and flexible prediction model with the final measured AUROC of 0.81 (95%CI 0.73–0.89). The percent dose change of bDMARDs, clinical disease activity (DAS-28 ESR), disease duration, and inflammatory markers were the most important predictors of a flare. Conclusion Machine learning methods were deemed feasible to predict flares after tapering bDMARDs in RA patients in sustained remission.

Keywords